Listed

TherapeuticsMD, Inc.: Form 10-K for the period ended Dec 31, 2017

Filed with the SEC on Feb 23, 2018 and accepted by EDGAR at Feb 23, 2018, 17:00 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2017-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Gross profit3 months2017-10-01 to 2017-12-31$3.5mus-gaap:GrossProfit
Gross profit12 months2017-01-01 to 2017-12-31$14.1mus-gaap:GrossProfit
Research and development12 months2017-01-01 to 2017-12-31$33.9mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative12 months2017-01-01 to 2017-12-31$57.7mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income12 months2017-01-01 to 2017-12-31−$77.6mus-gaap:OperatingIncomeLoss
Net income3 months2017-10-01 to 2017-12-31−$21.4mus-gaap:NetIncomeLoss
Net income12 months2017-01-01 to 2017-12-31−$76.9mus-gaap:NetIncomeLoss
Diluted EPS3 months2017-10-01 to 2017-12-31−$0.10us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS12 months2017-01-01 to 2017-12-31−$0.37us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow12 months2017-01-01 to 2017-12-31−$76.2mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2017-01-01 to 2017-12-31$61.8kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2017-12-31$127.1mus-gaap:Cash
Current assetsAt period end2017-12-31$139.6mus-gaap:AssetsCurrent
Total assetsAt period end2017-12-31$143.2mus-gaap:Assets
Current liabilitiesAt period end2017-12-31$13.3mus-gaap:LiabilitiesCurrent
Shareholders' equityAt period end2017-12-31$129.9mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001387131-18-000776. Last ingested by Listed: Nov 14, 2026, 19:24 ET. Listed shows no prices and gives no investment advice.